MC2078A1 - Emploi d'alezastine comme matiere active contre le psoriasis et des maladies inflammatoires - Google Patents

Emploi d'alezastine comme matiere active contre le psoriasis et des maladies inflammatoires

Info

Publication number
MC2078A1
MC2078A1 MC902086A MC2086A MC2078A1 MC 2078 A1 MC2078 A1 MC 2078A1 MC 902086 A MC902086 A MC 902086A MC 2086 A MC2086 A MC 2086A MC 2078 A1 MC2078 A1 MC 2078A1
Authority
MC
Monaco
Prior art keywords
alezastine
active ingredient
inflammatory diseases
ingredient against
against psoriasis
Prior art date
Application number
MC902086A
Other languages
English (en)
French (fr)
Inventor
Engel Juergen
Molliere Michael
Szelenyi Istvan
Original Assignee
Asta Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Ag filed Critical Asta Pharma Ag
Publication of MC2078A1 publication Critical patent/MC2078A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02F—DREDGING; SOIL-SHIFTING
    • E02F3/00—Dredgers; Soil-shifting machines
    • E02F3/04—Dredgers; Soil-shifting machines mechanically-driven
    • E02F3/18—Dredgers; Soil-shifting machines mechanically-driven with digging wheels turning round an axis, e.g. bucket-type wheels
    • E02F3/20—Dredgers; Soil-shifting machines mechanically-driven with digging wheels turning round an axis, e.g. bucket-type wheels with tools that only loosen the material, i.e. mill-type wheels
    • E02F3/205—Dredgers; Soil-shifting machines mechanically-driven with digging wheels turning round an axis, e.g. bucket-type wheels with tools that only loosen the material, i.e. mill-type wheels with a pair of digging wheels, e.g. slotting machines
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02F—DREDGING; SOIL-SHIFTING
    • E02F3/00—Dredgers; Soil-shifting machines
    • E02F3/04—Dredgers; Soil-shifting machines mechanically-driven
    • E02F3/88—Dredgers; Soil-shifting machines mechanically-driven with arrangements acting by a sucking or forcing effect, e.g. suction dredgers
    • E02F3/90—Component parts, e.g. arrangement or adaptation of pumps
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02F—DREDGING; SOIL-SHIFTING
    • E02F3/00—Dredgers; Soil-shifting machines
    • E02F3/04—Dredgers; Soil-shifting machines mechanically-driven
    • E02F3/88—Dredgers; Soil-shifting machines mechanically-driven with arrangements acting by a sucking or forcing effect, e.g. suction dredgers
    • E02F3/90—Component parts, e.g. arrangement or adaptation of pumps
    • E02F3/92—Digging elements, e.g. suction heads
    • E02F3/9212—Mechanical digging means, e.g. suction wheels, i.e. wheel with a suction inlet attached behind the wheel
MC902086A 1989-01-11 1990-01-04 Emploi d'alezastine comme matiere active contre le psoriasis et des maladies inflammatoires MC2078A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3900607 1989-01-11

Publications (1)

Publication Number Publication Date
MC2078A1 true MC2078A1 (fr) 1991-01-07

Family

ID=6371863

Family Applications (1)

Application Number Title Priority Date Filing Date
MC902086A MC2078A1 (fr) 1989-01-11 1990-01-04 Emploi d'alezastine comme matiere active contre le psoriasis et des maladies inflammatoires

Country Status (15)

Country Link
US (1) US5110814A (xx)
EP (2) EP0378086B1 (xx)
JP (1) JP2991733B2 (xx)
AT (2) ATE111735T1 (xx)
AU (1) AU618443B2 (xx)
CA (1) CA2007480C (xx)
DE (3) DE4000070A1 (xx)
DK (2) DK0533213T3 (xx)
EG (1) EG19912A (xx)
ES (2) ES2061307T3 (xx)
HK (2) HK50595A (xx)
IE (1) IE65336B1 (xx)
MC (1) MC2078A1 (xx)
PT (1) PT92821B (xx)
SG (2) SG30591G (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3190441B2 (ja) * 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
NL9201438A (nl) * 1992-08-11 1994-03-01 Prospa Bv Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
CZ199593A3 (en) * 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
US5569680A (en) * 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
DE19826517B4 (de) * 1998-06-15 2006-03-23 Baxter Healthcare S.A. Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette
DE10028638A1 (de) 2000-06-09 2001-12-20 Schuelke & Mayr Gmbh Lagerstabile Zusammensetzungen von Glycerinmonoalkylethern
CA2543689A1 (en) * 2003-10-31 2005-05-12 Hexal Ag Pharmaceutical actve-ingredient-containing formulation with coating
WO2005077963A1 (fr) * 2004-01-16 2005-08-25 Institut Superieur Agricole De Beauvais DErivEs de saccharides et d'itols possEdant un groupement O-alkyle ou un groupement O-alkyle et un groupement O-n-butanoyle. Applications comme mEdicaments dans les pathologies prolifEratives tumorales ou bEnignes.
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
SI2486942T1 (sl) 2004-11-24 2019-03-29 Meda Pharmaceuticals Inc. Sestavki, ki obsegajo azelastin, in postopki za njihovo uporabo
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
WO2014160440A1 (en) 2013-03-13 2014-10-02 Flatley Discovery Lab Pyridazinone compounds and methods for the treatment of cystic fibrosis
US10835584B2 (en) * 2016-06-17 2020-11-17 Nuvothera, Inc. Systems for treating dermal inflammatory conditions
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11938139B2 (en) * 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840606A (en) * 1969-12-05 1974-10-08 Oreal Process of producing mono and polyhydroxyl ethers
CH572914A5 (xx) * 1971-01-22 1976-02-27 Asta Werke Ag Chem Fab
DE3343530A1 (de) * 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
US4871733A (en) * 1984-04-09 1989-10-03 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs

Also Published As

Publication number Publication date
DE59007531D1 (de) 1994-12-01
CA2007480A1 (en) 1990-07-17
US5110814A (en) 1992-05-05
PT92821B (pt) 1995-12-29
DE59007288D1 (de) 1994-10-27
CA2007480C (en) 1995-08-15
SG30593G (en) 1995-09-18
ES2063841T3 (es) 1995-01-16
HK50595A (en) 1995-04-13
JPH02288827A (ja) 1990-11-28
AU4786290A (en) 1990-07-19
ATE113208T1 (de) 1994-11-15
DK0533213T3 (da) 1994-10-17
HK50495A (en) 1995-04-13
EP0378086B1 (de) 1994-10-26
IE65336B1 (en) 1995-10-18
EP0378086A3 (de) 1991-02-06
ATE111735T1 (de) 1994-10-15
DK0378086T3 (da) 1994-12-12
EP0533213B1 (de) 1994-09-21
IE900098L (en) 1990-07-11
AU618443B2 (en) 1991-12-19
DE4000070A1 (de) 1990-07-12
SG30591G (en) 1995-09-18
EP0533213A1 (de) 1993-03-24
PT92821A (pt) 1990-07-31
EG19912A (en) 1996-05-31
JP2991733B2 (ja) 1999-12-20
ES2061307T3 (es) 1994-12-01
EP0378086A2 (de) 1990-07-18

Similar Documents

Publication Publication Date Title
MC2078A1 (fr) Emploi d'alezastine comme matiere active contre le psoriasis et des maladies inflammatoires
IL100100A0 (en) Novel hydroxamic acid and n-hydroxyurea derivatives and their use
NO157020C (no) AnalogifremgangsmŸte ved fremstilling av terapeutisk aktive 3,20-dioxo-1,4-pregnadien-17alfa-ol-17-aromatiske heterocykliske carboxylater.
SE7903186L (sv) Cerebralverksamt medel
FI963424A (fi) Menetelmä terapeuttisesti aktiivisten tiofeenisulfonamidien valmistamiseksi
LU91125I2 (fr) Ranélate den strontium et ses dérivés pharmaceutiquement acceptables (protelos).
PT716600E (pt) Composicoes para administracao topica contendo derivados do acido 3-benzoilfenilacetico para o tratamento de doencas inflamatorias oftalmicas
NO146599C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 6-klor-2-(1`-piperazinyl)-pyrazin og salter derav
NO162557C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive (pyrrol-1-yl)-fenyldihydropyridazinoner.
GR3006674T3 (xx)
NO922136D0 (no) Anvendelse av gibberelliner for behandling av prostatitisog psoriasis
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
FI925518A (fi) Menetelmä terapeuttisesti aktiivisten 1-piperidinyylialkanoyyliaryylisulfonamidijohdannaisten valmistamiseksi
IT8448370A0 (it) Citrato trisodico utilizzabile nella cura delle malattie artriticoreumatiche
IT7945204A0 (it) Composizione farmaceutica per la terapia delle sterilita' maschile
IT8024347A0 (it) L'applicazione di 4-arilchinazolin-2(1h)-oni per il trattamento delle malattie autoimmuni dei tessuti connettivi.

Legal Events

Date Code Title Description
YP Annual fee paid